Structural Heart & Transcatheter Valves technology and investment research

Technical bottleneck

Why it's a moat — clinical trials, regulatory barriers, and installed-base lock-in

The PMA barrier: Structural heart devices require FDA Premarket Approval (PMA) — the highest regulatory hurdle in medtech. A PMA requires a randomized controlled trial (RCT) against surgery or best medical therapy, typically enrolling 500–2,000+ patients with multi-year follow-up. The PARTNER 3 trial (Edwards) enrolled 1,000 low-risk patients and just reported 7-year follow-up data at NY Valves 2026. The Evolut Low Risk trial (Medtronic) is at 6-year follow-up. A new entrant would need to run a similar trial — 7–10 years and $100M+ — against moving benchmarks. This is the deepest moat in medtech.

Durability is the battleground: As TAVR expands to younger patients (50–65 years), valve durability becomes the deciding factor. A surgical bioprosthetic valve lasts 10–15 years; TAVR valves must match or exceed this. The 7-year PARTNER 3 data showed SAPIEN 3 had comparable structural valve deterioration and reintervention rates vs. surgery — valves were holding up. Medtronic's CoreValve/Evolut platform at 8 years showed <3% reintervention. But differences are emerging: balloon-expandable (SAPIEN) may have advantages in coronary access for future procedures and lower permanent pacemaker rates; self-expanding (Evolut) may have larger effective orifice areas. These trade-offs create surgeon preference — and switching costs.

Lifetime management lock-in: A 55-year-old TAVR patient will likely need a second valve in 15–20 years. The second procedure is often a valve-in-valve TAVR (placing a new valve inside the old one) — and the new valve must be compatible with the old frame. Edwards' larger installed base (60%+ share in US TAVR) means more patients will return for Edwards-on-Edwards procedures. This is the installed-base flywheel: every valve placed today is a future valve-in-valve customer.

Mitral and tricuspid — the next wave: The mitral valve market is larger than aortic (more patients with mitral regurgitation) but technically harder — the mitral annulus is D-shaped, dynamic, and surrounded by critical structures (left ventricular outflow tract). Edwards' SAPIEN M3 (transseptal TMVR) just reported positive 1-year outcomes in MAC (mitral annular calcification) — a patient population with no surgical option. Tricuspid is even earlier — EVOQUE is the first approved TTVR device, with a market that could rival TAVR in volume over 10–15 years.

Adoption

Why it matters now

Edwards Lifesciences (EW):

• TAVR: SAPIEN 3 Ultra with RESILIA tissue (anti-calcification) — 7-year durability data solid; expanding to moderate/asymptomatic AS
• TEER: PASCAL Precision for mitral repair
• TMVR: SAPIEN M3 FDA approved; ENCIRCLE MAC trial 1-year data positive
• TTVR: EVOQUE tricuspid replacement; LAA clip FDA cleared 2026

Medtronic (MDT):

• TAVR: Evolut platform — 8-year data solid, self-expanding advantages in certain anatomies
• Broader structural heart + cardiac ablation (PFA) + leadless pacemakers (Micra)

Boston Scientific (BSX):

• Watchman FLX: left atrial appendage closure — facing slowdown but remains a $1B+ franchise
• FARAPULSE PFA: overlapping AFib market — structural heart adjacency
• Penumbra acquisition (pending $14.5B): neurovascular/stroke — another catheter-based intervention adjacency

Key trends

• Expansion to younger, lower-risk patients: EARLY TAVR trial supports intervention in asymptomatic severe AS — expanding TAM by 30–50%
• Valve-in-valve as the standard of care: As TAVR patients age, valve-in-valve procedures will dominate — favoring the installed-base leader
• Mitral and tricuspid as new TAM layers: Together could match or exceed TAVR in total addressable market within 15 years

Key players

Related Technologies

• Surgical Robotics — TAVR/structural heart procedures are the primary competitor to surgical robotics for aortic valve patients
• Medical Imaging Systems — TAVR requires CT for annular sizing and fluoroscopy/echo for procedural guidance
• Bioprocessing Consumables — tissue valves use bioprosthetic materials (bovine pericardium, porcine valves) processed through bioprocessing supply chains

Public companies exposed

• EW (Edwards Lifesciences)
• ABT (Abbott Laboratories)
• BSX (Boston Scientific)
• MDT (Medtronic)